器官晶片市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球器官晶片市场规模达1.47亿美元，预计年复合成长率将达29.7%，到2034年将达21亿美元。需求激增的驱动因素包括：迫切需要减少动物试验；组织工程和微流体技术不断取得突破；以及向精准医疗和简化药物开发的转变。此外，人们越来越倾向于更快、更具成本效益的临床前测试解决方案，以便提供对人体生理学的精准洞察。

全球慢性病发病率持续上升，这对医疗保健和研究系统造成越来越大的压力，迫使它们采用创新技术，以更深入地了解疾病的发展路径和治疗反应。这些疾病需要客製化的研究模型，这促使器官晶片 (OoC) 设备得到更广泛的应用。这些微型系统能够在体外模拟人体器官的功能，为以更贴近人体的方式研究疾病行为和药物效应提供了一种新方法。由于传统测试方法在准确性、时间和成本方面的限制，其实用性逐渐下降，OoC 平台正被视为医学研究和药物开发的变革性工具。

就类型而言，市场分为产品和服务。包括各种器官模拟晶片在内的产品细分市场在2024年占据最大份额，创造了1.108亿美元的收入。这些晶片复製了器官的生理和功能，为研究人员提供了更好的药物筛选和疾病建模工具。它们能够模拟真实的人体器官反应，这使得它们比传统的测试模型更具竞争优势。

依材料分析，聚二甲基硅氧烷 (PDMS) 在 2023 年占据市场主导地位，市占率为 42.9%。该材料因其优异的生物相容性、透明性和易于製造而脱颖而出。其灵活性使研究人员能够创建与人体组织高度相似的复杂器官晶片结构。基于 PDMS 的製造方法的技术改进提高了准确性、可扩展性和可重复性，这是推动器官晶片技术发展的关键因素。这反过来又推动了实验室和商业研究机构的采用，旨在开发支援复杂测试环境的模型。

根据模型类型，市场细分为单一器官模型和多器官模型。单器官晶片在2024年占据主导地位，预计2034年将达到11亿美元。这些模型因其简单、成本低且专注于特定的生理功能而备受青睐。它们能够针对性地评估药物毒性、药效学和疾病特异性反应，使其成为早期研究的首选。简单的维护和製造流程使其在学术和商业研究机构中广泛应用。

根据应用，器官晶片市场可分为药物研发、疾病建模、毒性测试、个人化医疗和其他用途。药物研发领域在2024年占据主导地位，预计2034年将成长至6.573亿美元。器官晶片系统的高准确度和预测能力使製药公司能够最大限度地减少药物开发过程中的反覆试验。这些系统减少了对动物试验的依赖，并提供了与人体相关的资料，有助于更早发现药物失败，并减少后期临床试验的损失。

就最终用户而言，市场细分为製药和生物技术公司、学术和研究机构以及其他领域。製药和生物技术领域在2024年的收入最高，预计2034年将达到14亿美元。该领域受益于降低开发成本、提高临床前测试精度以及降低人体试验相关风险的需求。各公司正在转向OoC技术，以便更精确地模拟人体组织，并更有效地测试对新候选药物的反应。

2024年，美国占据了5,690万美元的市场份额，从2022年的3,080万美元成长到2023年的4,260万美元，并维持了主导地位。预计2025年至2034年期间，美国市场的复合年增长率将达到28.6%。雄厚的科研资金、先进的医疗基础设施以及支持性的监管倡议等因素推动了该地区市场的成长。美国致力于探索动物试验的替代方案，并投入了大量的私人和公共资金，这些倡议将继续支持动物实验技术的推广。

领先的公司占据了约60%的整体市场份额，透过持续创新和推出新的、更先进的晶片模型来塑造行业格局。随着人们对针对个体生物学客製化解决方案的兴趣日益浓厚，器官晶片市场正迅速成为药物开发、安全测试和个人化医疗策略的重要组成部分。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性病盛行率不断上升
    • 个人化医疗需求日益增长
    • 器官晶片技术不断进步
    • 扩大器官晶片模型在生物医学应用的使用
  • 产业陷阱与挑战
    • 实施器官晶片技术的挑战与复杂性
    • 监管障碍阻碍市场成长
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供应方影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 产品
  • 肝臟晶片
  • 肺晶片
  • 心臟晶片
  • 肾臟晶片
  • 其他产品
• 服务

第六章：市场估计与预测：按材料，2021 - 2034 年

• 主要趋势
• 聚二甲基硅氧烷（PDMS）
• 聚合物
• 玻璃
• 其他材料

第七章：市场估计与预测：按车型，2021 - 2034

• 主要趋势
• 单一器官模型
• 多重器官模型

第八章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 药物研发
• 疾病模型
• 毒性测试
• 个人化医疗
• 其他应用

第九章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 製药和生物技术公司
• 学术和研究机构
• 其他最终用途

第十章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Altis Biosystems
• AlveoliX
• Axosim
• Beonchip
• Bi/ond Solutions
• Cherry Biotech
• CN Bio Innovations
• Emulate
• Hesperos
• InSphero
• MesoBioTech
• Mimetas
• NETRI
• React4Life
• TissUse

The Global Organ-On-Chips Market was valued at USD 147 million in 2024 and is estimated to grow at a CAGR of 29.7% to reach USD 2.1 billion by 2034. The surge in demand is driven by the urgent need to reduce animal testing, ongoing breakthroughs in tissue engineering and microfluidics, and the growing shift toward precision medicine and streamlined drug development. There is also a rising preference for faster, more cost-effective preclinical testing solutions that can provide accurate insights into human physiology.

Chronic diseases continue to rise globally, placing increasing pressure on healthcare and research systems to adopt innovative technologies that allow a deeper understanding of disease pathways and therapeutic responses. These conditions, which require tailored research models, have led to wider adoption of organ-on-chip (OoC) devices. These miniature systems mimic the functions of human organs in vitro, offering a new approach to studying disease behavior and drug effects in a more realistic and human-relevant manner. As traditional testing methods become less practical due to limitations in accuracy, time, and cost, OoC platforms are being recognized as transformative tools in medical research and pharmaceutical development.

In terms of type, the market is divided into products and services. The products segment, which includes various organ-mimicking chips, accounted for the largest share in 2024, generating USD 110.8 million in revenue. These chips replicate the physiological and functional aspects of organs, offering researchers better tools for drug screening and disease modeling. Their ability to imitate real-life human organ responses gives them a competitive edge over older testing models.

When analyzed by material, polydimethylsiloxane (PDMS) led the market in 2023, with a share of 42.9%. This material stands out due to its excellent biocompatibility, transparency, and ease of use in manufacturing. Its flexibility allows researchers to create intricate organ-on-chip structures that closely replicate human tissues. Technological improvements in PDMS-based fabrication methods have allowed for greater accuracy, scalability, and reproducibility, which are key factors in advancing organ-on-chip technologies. This, in turn, has fueled adoption across laboratories and commercial research facilities aiming to develop models that support complex testing environments.

Based on model type, the market is segmented into single organ models and multi-organ models. Single organ chips dominated in 2024 and are expected to reach USD 1.1 billion by 2034. These models are favored for their simplicity, lower cost, and focus on specific physiological functions. They enable targeted evaluation of drug toxicity, pharmacodynamics, and disease-specific responses, making them a preferred choice for early-phase studies. The straightforward maintenance and manufacturing processes make these chips practical for widespread use across academic and commercial research setups.

By application, the organ-on-chips market is categorized into drug discovery, disease modeling, toxicity testing, personalized medicine, and other uses. The drug discovery segment took the lead in 2024 and is projected to grow to USD 657.3 million by 2034. The high accuracy and predictive capabilities of OoC systems allow pharmaceutical companies to minimize trial and error during drug development. These systems reduce reliance on animal testing and provide human-relevant data, helping to identify drug failures earlier and reduce late-stage clinical trial losses.

Regarding end users, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others. The pharmaceutical and biotechnology segment held the highest revenue in 2024 and is anticipated to reach USD 1.4 billion by 2034. This segment benefits from the need to cut down on development costs, improve the precision of preclinical testing, and reduce the risks associated with human trials. Companies are turning to OoC technology to produce more accurate simulations of human tissues and test reactions to new drug candidates more effectively.

The United States accounted for USD 56.9 million of the market in 2024, maintaining its dominance after growing from USD 30.8 million in 2022 to USD 42.6 million in 2023. Between 2025 and 2034, the U.S. market is forecast to grow at a CAGR of 28.6%. Factors such as strong research funding, advanced healthcare infrastructure, and supportive regulatory initiatives have fueled market growth in the region. The country's commitment to exploring alternatives to animal testing, along with robust private and public investments, continues to support the expansion of OoC technologies.

Leading companies account for around 60% of the overall market share, shaping the industry landscape through continuous innovation and the launch of new, more advanced chip models. With growing interest in customized solutions tailored to individual biology, the organ-on-chips market is rapidly becoming an integral part of drug development, safety testing, and personalized medicine strategies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic disease
    • 3.2.1.2 Increasing demand for personalized medicine
    • 3.2.1.3 Growing advancement in organ-on-chip technology
    • 3.2.1.4 Expanding use of organ-on-chip models in biomedical applications
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Challenges and intricacies in implementing organ-on-chip techniques
    • 3.2.2.2 Regulatory obstacles hinder the market growth
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Liver-on-chip
  • 5.2.2 Lung-on-chip
  • 5.2.3 Heart-on-chip
  • 5.2.4 Kidney-on-chip
  • 5.2.5 Other products
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Polydimethylsiloxane (PDMS)
• 6.3 Polymer
• 6.4 Glass
• 6.5 Other materials

Chapter 7 Market Estimates and Forecast, By Model Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Single organ model
• 7.3 Multi-organ model

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Drug discovery
• 8.3 Disease modeling
• 8.4 Toxicity testing
• 8.5 Personalized medicine
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology companies
• 9.3 Academic and research institutes
• 9.4 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Altis Biosystems
• 11.2 AlveoliX
• 11.3 Axosim
• 11.4 Beonchip
• 11.5 Bi/ond Solutions
• 11.6 Cherry Biotech
• 11.7 CN Bio Innovations
• 11.8 Emulate
• 11.9 Hesperos
• 11.10 InSphero
• 11.11 MesoBioTech
• 11.12 Mimetas
• 11.13 NETRI
• 11.14 React4Life
• 11.15 TissUse